FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/02/103187 [Registered on: 06/02/2026] Trial Registered Prospectively
Last Modified On: 28/01/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A study comparing Magnesium and Dexamethasone as additives to Ropivacaine in ultrasound-guided adductor canal block for pain relief after total knee replacement surgery 
Scientific Title of Study   Efficacy of Magnesium Vs Dexamethasone as an adjuvant to Ropivacaine in Ultrasound guided Adductor Canal Block for postoperative analgesia in patients undergoing Total Knee Replacement surgery- A Prospective Double Blinded Randomized Controlled Study 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Saurabh Singh Chauhan 
Designation  PRIMARY DNB STUDENT  
Affiliation  FORTIS HOSPITAL LIMITED  
Address  FORTIS HOSPITAL LIMITED MULUND GOREGAON LINK ROAD , BHANDUP WEST MUMBAI 400078 INDIA

Mumbai (Suburban)
MAHARASHTRA
400078
India 
Phone  9584963024  
Fax    
Email  saurabhchauhan052@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr AMITA D. POTDAR 
Designation  CONSULTANT 
Affiliation  Fortis Hospital Limited,Mulund 
Address  FORTIS HOSPITAL LIMITED MULUND GOREGAON LINK ROAD , BHANDUP WEST MUMBAI 400078 INDIA

Mumbai
MAHARASHTRA
400078
India 
Phone  9584963024  
Fax    
Email  dramitapotdar@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Saurabh Singh Chauhan 
Designation  DNB student 
Affiliation  Fortis Hospital Hosptal, Mulund 
Address  FORTIS HOSPITAL LIMITED MULUND GOREGAON LINK ROAD , BHANDUP WEST MUMBAI 400078 INDIA

Mumbai
MAHARASHTRA
400078
India 
Phone  9584963024  
Fax    
Email  saurabhchauhan052@gmail.com  
 
Source of Monetary or Material Support  
fortis hospital mumbai mulund goregaon link road industrial area 400078 
 
Primary Sponsor  
Name  fortis hospial mumbai 
Address  mulund goregaon link road indusrial area bhandup west 400078 
Type of Sponsor  Private hospital/clinic 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Saurabh Singh Chauhan  Operation Theatre,Fortis Hospital limited   Fortis Hospital limited Mulund goregaon linkroad, Bhandup west Mumbai 400078 maharastra india
Mumbai (Suburban)
MAHARASHTRA 
9584963024

saurabhchauhan052@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
institutional ethics committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: M171||Unilateral primary osteoarthritisof knee,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Dexamethasone + ropivacaine   Dose- 4mg dexamethasone + 20ml 0.2% ropivacaine Frequency- Single shot Route of administration- Perineural injection (Regional anesthesia) under USG Duration- 24 hours 
Intervention  Magnesium sulphate + Ropivacaine  Dose- 250mg Magnesium sulphate + 20ml 0.2 % Ropivacaine Frequency- Single shot Route of administration- Perineural injection (Regional anesthesia) under USG Duration- 24 hours 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  85.00 Year(s)
Gender  Both 
Details  ASA PHYSICAL STATUS 1 to 3
single knee surgery  
 
ExclusionCriteria 
Details  Bilateral knee surgery in one sitting
History of allergy to local anaesthetics or study drugs- magnesium or dexamethasone
Opioid addiction
Local infection
Patient refusal
Patients with a neuropsychiatric disorder
Pregnant or lactating women
 
 
Method of Generating Random Sequence   Random Number Table 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
Decrease in the total Opioid Consumption in post operative period in patients undergoing Total Knee Replacement
 
Postoperative 
 
Secondary Outcome  
Outcome  TimePoints 
NRS score on movement-(knee bend,walk

 
Postoperative 
NRS score at rest  Postoperative 
Need of rescue analgesic  Postoperative 
Nausea & vomiting  Postoperative 
Patient Satisfaction  Postoperative 
 
Target Sample Size   Total Sample Size="52"
Sample Size from India="52" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   20/02/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

My study is "Efficacy of Magnesium Vs Dexamethasone as an adjuvant to Ropivacaine in Ultrasound guided Adductor Canal Block for postoperative analgesia in patients undergoing Total Knee Replacement surgery: A Prospective, Double Blinded Randomized Controlled Study"

Type of study: Prospective Randomized controlled observational double blind study

Patient age-group : 18 year to 85year 

 diagnosis:    osteoarthritis

Procedure of study:

1. After clearance from institutional ethical committee, Patients undergoing unilateral TKR surgery will be recruited for our study.

2.They will be randomly allocated by computer generated randomization number into two groups.

Group D (Ropivacaine + Dexamethasone & Group M (Ropivacaine + MgSO4)

3. During Pre-Anesthesia Checkup (PAC) patients will be introduced to pain NRS (Numerical Rating Scale), CADD PCA (Patient Controlled Analgesia) and will be informed about the study.

4. Written informed consent will be obtained from each patient.

5. Choice of anesthesia (GA/SA) for surgery will be as per the attending anesthesiologist.

Pre-incision USG guided ADDUCTOR CANAL BLOCK –

The group allocation list will be discreetly shared with the attending anesthesiologist who will prepare the study drug syringes as per the sequence number and assigned patients to the trial groups.

The study drugs will be prepared in an identical syringes as colorless solutions for administration to ensure blinding.

Patients will be subsequently followed up by a researcher who is unaware of the group allocation.

Thus effectively, the anesthesiologist performing the block will not be blinded to the procedure, but the patient and assessor of pain NRS were blinded to group allocation.

The anesthesiologist perform the block will be registered  under PCPNDT registration.

ADDUCTOR CANAL BLOCK PROCEDIURE

Patient will be in supine position on operating table under anesthesia with all standard monitoring.

The side to be operated is reconfirmed with surgery team as part of safe surgical checklist and positioned with external rotation knee slightly  flex

The block area will be prepared with 5% povidone iodine and cordoned off by surgical drapes

A linear transducer of USG machine (GE VENUE GO) will be cleaned, lubricated with sono jelly and draped in a sterile plastic cover.

The medial aspect of the thigh will be scanned in a transverse axial plane using the linear probe to obtain a short-axis view of the femoral artery at the mid-femoral level.

If the artery is not immediately obvious, several maneuvers can be used to identify it, including color Doppler scanning to trace the femoral artery caudally from the inguinal crease.

Once the femoral artery has been identified, the probe will be moved distally to trace the femoral artery to the point at which it deviates posteriorly into the popliteal fossa indicating its passage through the adductor hiatus to become the popliteal artery. At this point, the saphenous nerve continues its original course just underneath the sartorius muscle.

At a distance of no more than 7cm proximal to the medial condyle, a short-axis view of the sartorius and vastus medialis muscles will be obtained with the saphenous nerve identified between the two muscles.

The operator will use an in-plane approach and will advance the needle from lateral to medial into the adductor canal through sartorius or vastus medialis, aspirated and injected a test dose of 1 ml of the normal saline solution, will observe the spread to ensure the needle tip in the adductor canal.

If  the intravascular placement of the needle is seen or if no spread of saline solution is seen then the operator will reposition the needle and will repeat the previous step again.

After confirming the target location of the needle tip, the injection of the 21 mL of study drug solution will be given in aliquots of 2- 3 ml and aspirating every 5 ml to rule out any intravascular injection.

Group D  will receive 20 ml of 0.2% of Ropivacaine with 4 mg of Dexamethasone in 1 ml while Group M will receive 20 ml of 0.2% of Ropivacaine with 500 mg of MgSO4 in 1 ml.

Primary Outcome:  total Opioid Consumption in post operative 24 hour  period in patients undergoing TKR.

 Secondary Outcome:  

VAS score on movement – (knee bend +/-walk )

 VAS score at rest

Need of rescue analgesic

Nausea & vomiting

Patient satisfaction

Based on the outcome what type of analysis and data collection:

The duration of study will be from IEC approval date till 18 months and 52 no. of patients will be included in this study.

Data analysis will be done by statistical tests and results obtained may be published in journal.

Patient Information Sheet will be provided to all patients. Patient Information Sheet will contain methodology, risks, and benefits of the study and before enrolling patients in the study, Informed Consent will be taken from them. No active intervention will be done by the Primary Investigator. The study will be done after approval from Institutional Ethics Committee is granted.

 
Close